07:00 , May 16, 2016 |  BioCentury  |  Finance

Global ambitions

European biotechs not only missed out on the extended bull market that allowed U.S. biotechs to fill their coffers, but also on what could have been an arbitrage opportunity for U.S. investors who found domestic...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Financial News

UCL financial update

The European Investment Fund (EIF) and Imperial Innovations Group plc (LSE:IVO, London, U.K.) each invested L24.8 million ($35.4 million). Albion Ventures will manage the fund. University College London , London, U.K.   Business: Finance  ...
02:11 , Jan 20, 2016 |  BC Extra  |  Financial News

UCL launches L50M fund

University College London launched the UCL Technology Fund with L50 million ($71.5 million), which it plans to invest over five years in academic research it believes has commercial potential, including licensing projects and new spinouts...
07:00 , May 25, 2015 |  BC Week In Review  |  Financial News

Abcodia completes venture financing

Abcodia Ltd. , London, U.K.   Business: Diagnostic, Pharmacogenetics   Date completed: 2015-05-18   Type: Venture financing   Raised: L5.3 million ($8.2 million)   Investors: Cambridge Innovation Capital plc; Scottish Equity Partners; Albion Ventures; UCL...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Clinical News

Greer short ragweed sublingual allergen immunotherapy liquid: Phase III data

A double-blind, North American Phase III trial in 429 patients ages 18-55 with moderate to severe allergic rhinoconjunctivitis showed that once-daily RW-SAIL met the primary endpoint of reducing average TCS from baseline over the entire...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Company News

Stallergenes, Greer sales and marketing update

Stallergenes granted Greer exclusive, U.S. commercialization rights to Oralair , a sublingual therapy against five grass allergens. Stallergenes is eligible for regulatory and commercial milestones of up to $120 million, plus royalties and an undisclosed...
07:00 , May 13, 2013 |  BC Week In Review  |  Company News

Albion, Ares Life Sciences deal

Investment group Ares completed its acquisition of Albion, including wholly owned subsidiary Greer Laboratories Inc. (Lenoir, N.C.). The companies could not be reached for details (see BioCentury, March 18). Albion Medical Holdings Inc. , Lenoir,...
07:00 , Apr 15, 2013 |  BioCentury  |  Emerging Company Profile

Abcodia: Banking on biomarkers

Abcodia Ltd. is using blood samples that have been taken annually by the U.K. Collaborative Trial for Ovarian Cancer Screening to identify serum biomarkers that can detect breast, lung, pancreatic and colorectal tumors at least...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Albion Medical Holdings Inc., Ares Life Sciences deal

Investment group Ares will acquire 100% of the share capital of Albion, including wholly owned subsidiary Greer Laboratories Inc. (Lenoir, N.C.). Greer recently completed a Phase III trial with its sublingual allergy immunotherapy liquid (SAIL)...
08:00 , Feb 13, 2012 |  BC Week In Review  |  Financial News

Xceleron completes venture financing

Xceleron Ltd. , York, U.K.   Business: Supply/Service, ADMET   Date completed: 2/6/12   Type: Venture financing   Raised: $2.4 million   Investors: Albion Ventures; Solon Ventures  ...